Voronoi, Inc. (310210.KQ)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Hyuntae Kim | CEO & Director | -- | -- | 1976 |
| Mr. Sangjin Lee | Chief Financial Officer | -- | -- | -- |
| Mr. Sangjin Woo | COO & Director | -- | -- | 1976 |
| Mr. Hosey Hwang | Director of Accounting | -- | -- | -- |
| Sunghwan Kim Ph.D. | Chief Science Officer & Director of Biology Research | -- | -- | -- |
Voronoi, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 139
Description
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available